

# Oliver S Eng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7289023/publications.pdf>

Version: 2024-02-01

45  
papers

409  
citations

949033

11  
h-index

993246

17  
g-index

45  
all docs

45  
docs citations

45  
times ranked

599  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. <i>Journal of Surgical Oncology</i> , 2022, 125, 560-563.                                | 0.8 | 6         |
| 2  | Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 29-29.  | 0.8 | 1         |
| 3  | Survival in total preoperative versus perioperative chemotherapy for patients with metastatic high-grade appendiceal adenocarcinoma undergoing CRS/HIPEC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 90-90.               | 0.8 | 0         |
| 4  | Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 312-312.                    | 0.8 | 1         |
| 5  | Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. <i>JCO Precision Oncology</i> , 2022, 6, e2100337.                               | 1.5 | 4         |
| 6  | A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. <i>Surgical Oncology</i> , 2021, 37, 101492.   | 0.8 | 15        |
| 7  | Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. <i>British Journal of Cancer</i> , 2021, 124, 564-566.  | 2.9 | 18        |
| 8  | Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1777-1785. | 0.7 | 4         |
| 9  | Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Advanced Colorectal or Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7795-7806.  | 0.7 | 8         |
| 10 | ASO Author Reflections: Disparities in Access to Cytoreductive Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 7807-7808.   | 0.7 | 0         |
| 11 | ASO Visual Abstract: Differences in Sociodemographic Disparities in Patients Undergoing Surgery for Advanced Colorectal and Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 430-431.                             | 0.7 | 1         |
| 12 | Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC. <i>Annals of Surgical Oncology</i> , 2021, 28, 6955-6964.                          | 0.7 | 8         |
| 13 | Gastrointestinal Surgical Emergencies in the Neutropenic Immunocompromised Patient. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 3258-3264.   | 0.9 | 7         |
| 14 | Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4433-4443.   | 0.7 | 4         |
| 15 | Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy" <i>British Journal of Cancer</i> , 2021, 124, 1179-1180.                          | 2.9 | 3         |
| 16 | Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325.                     | 7.7 | 49        |
| 17 | Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 155-164.                   | 0.9 | 27        |
| 18 | Health-related quality of life and oncologic outcomes after surgery in older adults with colorectal cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 2857-2865.   | 1.0 | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. <i>Annals of Surgical Oncology</i> , 2020, 27, 630-631.      | 0.7 | 4         |
| 20 | Getting to the Root of the Problem. <i>Gastroenterology</i> , 2020, 158, 1229-1231.   | 0.6 | 0         |
| 21 | The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis. <i>Journal of Surgical Research</i> , 2020, 248, 20-27.   | 0.8 | 11        |
| 22 | Peritoneal Metastases in Colorectal Cancer: Biology and Barriers. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 720-727.   | 0.9 | 17        |
| 23 | Complete Response in a Patient With Chemorefractory <i>EGFR</i> -Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. <i>JCO Precision Oncology</i> , 2020, 4, 1180-1186. | 1.5 | 6         |
| 24 | Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4980-4995.                       | 0.7 | 15        |
| 25 | Cancer Surgery During COVID-19. <i>Annals of Surgery</i> , 2020, 272, e94-e95.  | 2.1 | 7         |
| 26 | Apples to Oranges. <i>Annals of Surgery</i> , 2020, 272, e52.   | 2.1 | 5         |
| 27 | The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. <i>International Journal of Hyperthermia</i> , 2020, 37, 1182-1188.  | 1.1 | 5         |
| 28 | Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. <i>Annals of Surgical Oncology</i> , 2020, 27, 5039-5046.  | 0.7 | 4         |
| 29 | Assessment of the Surgical Workforce Pertaining to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the United States. <i>Annals of Surgical Oncology</i> , 2020, 27, 3097-3102.  | 0.7 | 14        |
| 30 | HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 551-553.   | 1.2 | 3         |
| 31 | Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. <i>Journal of Surgical Oncology</i> , 2020, 122, 980-985.                       | 0.8 | 10        |
| 32 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve. <i>Journal of Surgical Oncology</i> , 2020, 122, 85-95.   | 0.8 | 9         |
| 33 | Implementation of bundled care to reduce surgical site infections after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2019, 120, 1044-1045.                                      | 0.8 | 1         |
| 34 | A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 338-344.   | 0.7 | 4         |
| 35 | Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. <i>Journal of Surgical Oncology</i> , 2019, 119, 613-615.  | 0.8 | 23        |
| 36 | Robotic total pancreatectomy with splenectomy: technique and outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 3691-3696.   | 1.3 | 10        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Fluids in abdominal surgery: what is the goal?. Hepatobiliary Surgery and Nutrition, 2018, 7, 227-228.  | 0.7 | 1         |
| 38 | Quality of Life, Symptoms, and Self-Management Strategies After Gastroesophageal Cancer Surgery. Journal of Pain and Symptom Management, 2018, 56, e4-e8.                     | 0.6 | 6         |
| 39 | Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy. Surgical Infections, 2018, 19, 618-621.      | 0.7 | 8         |
| 40 | Academic productivity in surgical oncology: Where is the bar set for those training the next generation?. Journal of Surgical Oncology, 2018, 118, 397-402.                   | 0.8 | 12        |
| 41 | A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer. Journal of Surgical Oncology, 2018, 118, 121-126.                     | 0.8 | 8         |
| 42 | Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2017, 24, 2707-2711.        | 0.7 | 9         |
| 43 | Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. JAMA Surgery, 2017, 152, 1156.                    | 2.2 | 52        |
| 44 | Predictors of survival after trimodality therapy for esophageal adenocarcinoma: Analysis from the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 116-116. | 0.8 | 0         |
| 45 | Operative bed recurrence of thyroid cancer: utility of a preoperative needle localization technique. Gland Surgery, 2016, 5, 571-575.   | 0.5 | 4         |